What's in Spine BioPharma, Inc's pipeline?

Spine BioPharma, Inc has 2 drugs in our index: 0 marketed, 0 filed, 2 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Spine BioPharma, Inc's portfolio?

Top competitors by shared drug class: Mohanad Al-Sabbagh, University of Louisville, University of Sao Paulo.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/spine-biopharma-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Spine BioPharma, Inc — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Spine BioPharma, Inc pipeline: 0 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
SB-01 For Injection	SB-01 For Injection	phase 3	Bone graft substitute		Orthopedics
Sham Needle	Sham Needle	phase 3

Therapeutic area mix

Orthopedics · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Mohanad Al-Sabbagh · 1 shared drug class
University of Louisville · 1 shared drug class
University of Sao Paulo · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Spine BioPharma, Inc:

Cite this brief

Drug Landscape (2026). Spine BioPharma, Inc — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/spine-biopharma-inc. Accessed 2026-05-16.